Please login to the form below

Not currently logged in

BIA launches R&D communications best practice guide

Aims to support UK bioscience groups interacting with investors and the public

BIAThe UK BioIndustry Association (BIA) has launched a new guide to assist bioscience companies communicate their R&D progress to its investors and the public.

Driven by the UK’s ‘booming’ bioscience landscape, the Best Practice Guide presents four principles for high-quality communications that both public and private bioscience companies should follow.

“Be well prepared” and “be consistent” are among the advice that the guide offers, along with “be fair, balanced and understandable” and “be mindful of the impact on members of the public to whom it is personally relevant”.

Dr Chris Gardner, partner at Consilium Strategic Communications, said: “With bioscience companies expected to play an ever more pivotal role in the UK economy, the need for clear and effective communication has never been greater.

“Distilling complex ideas in high science companies for multiple audiences can be challenging, but there are some basic approaches which can help them keep their messages clear and simple.”

The BIA said its new guide is designed to help bioscience groups meet sector best practice and to apply their communications to the R&D process in particular.

Steve Bates, chief executive officer of BIA, said: “To establish the UK as the third global bioscience cluster we need investors and the public to be well informed and confident about the great science our companies our doing.”

The Best Practice Guide’s launch comes ahead of this month’s 36th annual JP Morgan Healthcare conference, a high point of the biotech calendar that will see entrepreneurs and investors from the UK sector attend.

Bates added: “As the entrepreneurial leaders and investors attend the JP Morgan in San Francisco, we hope the this guide helps them communicate the great investment opportunities there are here in Britain.”

Article by
Gemma Jones

4th January 2018

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...